Breathe Well Live Well
|
Demographic Characteristics of Asthma Subjects Associated With Stepping Down …
AJMC.com Managed Markets Network Methods: Subjects were included if they: 1) had ?2 FSC prescription claims prior to the index (step-down) date, 2) had ?1 asthma claim, 3) were aged 12 to 64 years, and 4) were continuously eligible for 12 months pre- and post index. Subjects were … |
View full post on asthma – Google News
|
Research and Markets: United States Asthma Drugs Market 2015-2019 …
Yahoo Finance UK The report, Asthma Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes … |
View full post on asthma – Google News
|
Research and Markets: Frontier Pharma: Asthma – Identifying and …
Business Wire (press release) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News
|
An overview of the global markets for nebulizers, inhalers, and respirators …
Virtual Press Office (press release) The report is a comprehensive business tool designed to provide an in-depth look at equipment related to asthma. The report is global in geographical scope, with special emphasis on individual regions. The report describes the industry, its … |
View full post on asthma – Google News
|
Nebulizers, Inhalers and Respirators for Asthma Treatment: Global Markets
PR Newswire (press release) The report is a comprehensive business tool designed to provide an in-depth look at equipment related to asthma. The report is global in geographical scope, with special emphasis on individual regions. The report describes the industry, its … |
View full post on asthma – Google News
|
Research and Markets: GSK's Flovent (Asthma) – Forecast and Market Analysis …
Business Wire (press release) Originally approved by the Food and Drug Administration (FDA) in 1996, GSK's Flovent (fluticasone propionate) is a synthetic ICS therapy with potent anti-inflammatory activity. It is used for the maintenance treatment of asthma prophylactically in … Research and Markets: GSK's Bosatria (Mepolizumab) Asthma Treatment … |
View full post on asthma – Google News
|
Research and Markets: Roche's Quilizumab (Asthma) – Forecast and Market …
Business Wire (press release) IgE is important in the development of allergic asthma, as it binds to mast cells and basophils, which play a significant role in the pathogenesis of asthma. IgE ultimately triggers the release of histamines, prostaglandins, and leukotrienes, which … Research and Markets: Cinquil (Reslizumab) Asthma Treatment – Forecast and … Research and Markets: Roche's Lebrikizumab (Asthma) Treatment – Forecast … |
View full post on asthma – Google News
|
Research and Markets: Roche/Genentech/Novartis' Asthma Treatment – Xolair …
Business Wire (press release) Roche/Genentech/Novartis' Xolair (omalizumab) is currently the only FDA-approved biologic used in the treatment of asthma. This drug is a recombinant humanized mAb that binds and neutralizes IgE with the same high affinity as its cognate receptor, FceRI. Research and Markets: Merck's Dulera Asthma Treatment – Forecast and Market … |
View full post on asthma – Google News
|
Research and Markets: PharmaPoint: Asthma – 5EU Drug Forecast and Market …
Rock Hill Herald (press release) The relatively slow growth of the German market compared with the French, Spanish, and UK markets is attributable to the slightly decreasing prevalence of asthma in this country over the forecast period. Advair's active patent on the Diskus delivery … |
View full post on asthma – Google News
|
Initiation of Inhaled Corticosteroid and Long-Acting b2-adrenergic Agonist …
AJMC.com Managed Markets Network Study Design: The current study is a retrospective cohort analysis of patients with asthma, aged 12 to 64 years, new to ICS/LABA combination therapy, using—US healthcare claims data between June 1, 2007, and December 31, 2010. Methods: Patients with … |
View full post on asthma – Google News